AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial. 

Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).

EMPEROR-Preserved was a phase 3, randomized, double-blind trial, where patients with HFpEF receive a daily dose of either empagliflozin, a sodium–glucose cotransporter 2 inhibitor, or placebo. In this analysis, researchers hypothesized that the objective evidence of diastolic dysfunction (DD) in HFpEF could predict the response to empagliflozin. DD was defined as the presence of LAVI ≥34 mL/m2, E/e ≥13 or LVMi >115 (males) or >95 (females). Baseline echocardiographic diastolic dysfunction incrementally predicted clinical response to Empagliflozin, suggesting a targeted mechanism of action on diastolic performance.

Interview Questions:
1.    What is the current research landscape for empagliflozin in treating HFpEF, and why is the trial important?
2.    What was the study design and patient population of EMPEROR-Preserved?
3.    What were the key findings?
4.    What are the take-home messages?
5.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.